GeoVax Labs, Inc. GOVX

GOVX Company Overview

GeoVax Labs, Inc. is a U.S.-based clinical-stage biotechnology company focused on the development of human vaccines for infectious diseases and cancer immunotherapy. The company operates within the biotechnology and life sciences industries, with an emphasis on vaccines that address large unmet medical needs. GeoVax does not currently generate commercial product revenue and is primarily funded through a combination of government grants, public offerings, and strategic partnerships.

The company’s core value proposition centers on its proprietary Modified Vaccinia Ankara–Virus-Like Particle (MVA‑VLP) vaccine platform, designed to induce both humoral and cellular immune responses. GeoVax was founded in 2001 and has evolved from early HIV vaccine research into a broader infectious disease and oncology-focused vaccine developer, expanding its pipeline to include COVID‑19, Ebola, Sudan virus, Marburg virus, and cancer immunotherapy candidates.